Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

MGB Biopharma Limited

http://www.mgb-biopharma.com/

Latest From MGB Biopharma Limited

Early Results For Therapyx/Intravacc's Vaccine May Herald Progress In Gonorrhea Prevention

Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.

Deals Vaccines

Scotland's MGB Bags More Funds To Tackle Antibiotic Resistance

The Glasgow-based group has raised more cash to take its new class of anti-infective through Phase IIa trials for C diff-associated disease.

Financing Infectious Diseases

War on C Difficile Is Being Fought On Multiple Fronts

Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.

Infectious Diseases Research & Development

Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity

Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.

Infectious Diseases Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register